Patent details

LUC00230 Product Name: Rémimazolam ou un de ses sels pharmaceutiquement acceptables

Basic Information

Publication number:
LUC00230
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP137301289
Legal Status:
Inactive
Application number:
LUC00230
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1505
Marketing Authorization Type:
Marketing Authorization Date:
29/03/2021
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
20/09/2021
First Marketing Authorization date:
29/03/2021
Grant date:
07/10/2022
Activation date:
Publication date:
21/09/2021
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
29/03/2036
SPC Extension Expiration:
29/03/2036
Rejection date:
Withdrawal date:

Owner

From:
20/09/2021
 
 

Name:
PAION UK Limited
Address:
Kew Road 5, Parkshot House, Unit 302, TW9 2PR, Richmond, London , United Kingdom (GB)

Agent

Name:
ARONOVA S.A.
From:
20/09/2021
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2021/11
Publication date:
08/10/2021
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2022/12
Publication date:
08/11/2022
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/05/2033
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
21/09/2021 Publication 1
07/10/2022 Publication 1
07/10/2022 Certificate 1
10/10/2022 Outgoing Correspondence 1
20/09/2021 Summary of the product caracteristics 31
20/09/2021 Marketing authorization 3
21/09/2021 Outgoing Correspondence 1
20/09/2021 Application Form 4
20/09/2021 MA publication 2
20/09/2021 General Document 2